Fariba Ghaidi

TL;DR: By inducibly suppressing AR expression in vivo, there is an extensive delay in progression to androgen independence as well as a dramatic inhibition of tumor growth and decrease in serum PSA, which exceeds that seen with castration alone.

TL;DR: Evaluation of the molecular phenotype of differentiated thyroid cancer (DTC) and benign thyroid tumor molecular phenotype has allowed for identification of a marker panel, composed of both established and novel markers, useful for thyroid cancer diagnosis.

TL;DR: Results demonstrate proof-of-principal that small molecule targeting of the ERG-ETS domain can suppress transcriptional activity and reverse transformed characteristics of prostate cancers aberrantly expressing ERG.

TL;DR: Among compounds identified that effectively inhibit Myc-Max activity with low to mid-micromolar range potency and no or minimal generic cytotoxicity, VPC-70067, a close analog of the previously identified Myc inhibitor 10058-F4, served as proof-of-concept that the in silico drug discovery strategy performed as expected.

TL;DR: This study reports compound VPC-80051 as the first small molecule inhibitor of hnRNP A1 splicing activity discovered to date by using a computer-aided drug discovery approach and lays the groundwork for future structure-based development of more potent and selective small molecule inhibitors of hmR NP A1–RNA interactions aimed at altering the production of cancer-specific alternative splice isoforms.